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Abstract
Introduction: Inflammatory conditions modulated by Chlamydophila (Chlamydia)
pneumoniae  are considered to play an important role in the onset of
atherosclerosis. In this paper we present the results of progressive observation
of C. pneumoniae antibody titres in patients who underwent coronary artery
bypass graft (CABG).
Material and methods: The objective of our research was a prospective
observation of antibody titres in IgA and IgG class antibodies against 
C. pneumoniae using indirect immunofluorescence in a group of 155 post-surgery
CABG patients suffering from heart ischaemia. The microbiological test results
were compared with patients’ present coronary complaints evaluated on the
CCS scale during a six-year period.
Results: Six years after CABG, 128 patients (82.6%) are still alive. During the
study a positive serological conversion of antibody titres was observed in 36
patients in the IgA class antibodies, and in 26 patients in the IgG class. The
group of patients with no antibodies against C. pneumoniae decreased from
23.2 to 3.4%, while the group of patients with antibodies in both IgG and IgA
classes increased from 52.3 to 83.9%. The average CCS degree decreased from
3.18 before CABG to 1.65 in the present study.
Conclusions: These results show no connection between the serological
symptoms of chronic C. pneumoniae infection and coronary complaints evaluated
on the CCS scale during a six-year study on post-CABG patients suffering from
heart ischaemia. The surgical treatment of heart ischaemia brought about long-
term improvement in the coronary condition of the observed group of patients. 
Key words: atherosclerosis, Chlamydophila (Chlamydia) pneumoniae, coronary
artery bypass graft, progressive examination.
Introduction
Damage of the endothelium is considered to be crucial in the onset of
atherosclerosis. It leads to increase in T lymphocyte adhesion, release of
numerous cytokines, and then to proliferation of smooth muscle. As a result
of the process atherogenesis, atheromatosus plaque are formed. They
cause limitation of the coronary reserve, which manifests as patients’
coronary complaints. In addition to well-known, classical risk factors which
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Antibodies against C. pneumoniae Score  Antibodies against C. pneumoniae Score
IgA (–) None 0A IgG (–) None 0G
IgA (+) 1 : 50 1A IgG (+) 1 : 100 1G
IgA (+) 1 : 100 2A IgG (+) 1 : 1000 2G
Table I. Classification of antibody titres against C. pneumoniae
can initiate the atherogenesis, some bacterial and
viral infections are also considered to play a role in
the aetiology of CAD. Chlamydophila pneumoniae
(C. pneu  moniae), responsible for atypical bronchitis
and pneumonia, is in the range of interest of some
researchers. A chronic C. pneumoniae infection
shows a modulating influence on the development
of atherosclerosis, thus increasing the level of
independent risk factors for coronary disease, such
as acute phase protein or LDL cholesterols [1-4].
Saikku  et al. [5] were the first to notice the
appearance of antibodies against C. pneumoniae in
patients suffering from coronary artery disease and
myocardial infarction. Thom et al. [6] in their paper
showed that an elevated level of antibodies against
C. pneumoniae increases the probability of
development of coronary artery disease almost
three times. 
A common method of diagnosing C. pneu  -
moniae-triggered-inflammations is to examine
patient’s serum for species-specific IgM, IgG and
IgA class antibodies. Determining the dynamics of
appearance and disappearance of particular
immunoglobulin classes allows one to diagnose
what kind of infections the patient suffers from:
primary, chronic, or reinfection. In an acute primary
infection, IgM class antibodies appear first and their
levels remain increased for about 2 months, to
gradually subside later. Next, the IgG class antibody
titre levels increase, and then the same elevation
is noticed in the IgA class. In case of successful
treatment and no reinfection, the antibody levels
slowly decrease, despite the fact that elevation in
IgG class antibody levels is usually observed
proportionally to the patient’s age. Increased, but
remaining stable, the level of IgG class antibodies,
and, in particular, IgA class antibodies may indicate
a chronic infection and/or frequently reoccurring
infections [7].
The objective of this study was to compare the
C. pneumoniae antibody levels in 118 patients
treated surgically for coronary artery disease
preoperatively and after six years of follow-up. In
this study we also tried to evaluate the influence
of C. pneumoniae infection on the late results of
surgical treatment of CAD.
Material and methods
The study was conducted between 1999 and
2000 (2000 Study) and between 2005 and 2006
(2006 Study). Both studies were financed by the
State Committee for Scientific Research from the
Science and Research Fund: KBN 4P05C05815 and
2P05C03529.
For the 2000 Study 155 patients with diagnosed
CAD caused by disseminated stenoses and
scheduled for elective surgical treatment were
chosen. All patients were operated on with
extracorporeal circulation. Patients with poor
ejection fraction, operated on emergently and with
stenoses in one or two vessels were excluded from
the study. The group consisted of 31 women (20%),
mean age 61.65 ±8.7 years, and 124 men (80%),
mean age 56.36 ±8.9 years. Their preoperative
coronary complaints were evaluated according to
the CCS scale (8,9). Before the operation 2 patients
(1.3%) were in CCS class I, 19 patients (12.3%)
reported coronary pains in class II, and 81 patients
(52.3%) in class III. Fifty-three patients (34.2%)
reported pains at rest (CCS class IV). The average
degree on the CCS scale in 155 patients was 3.13.
Ninety-two patients (59.4%) had myocardial
infarction in the past. The 2006 Study was
conducted 6 years after the surgery (mean 83.4
months, ±3.6), on the same group of patients, and
included laboratory and general examination. Risk
factors for progression of atherosclerosis (e.g.
diabetes, hypertension, smoking history, obesity,
etc.) were the same, but more patients in the 2006
Study were on statins and antiaggregants. These
values were not statistically significant. The
antibody titres in IgG and IgA classes against 
C. pneumoniae were measured in those patients
preoperatively and six years after the surgery using
indirect immunofluorescence (Euroimmun,
Germany). 1 : 50 solution for IgA class and 1 : 100
for IgG class was assumed to be positive (Table I).
For the purpose of statistical analysis and avoidance
of division into smaller groups, each titre value of
antibodies was assigned a specific score. Depending
on the dilution of solution in which the antibodies
were detected, their corresponding titres were
assigned a point score (Table II). Adding the scores
for detecting antibodies in particular IgA and IgG
antibody titres, we received qualification which
allowed for a statistical analysis of the degree of 
C. pneumoniae infection in patients (Table III). 
The data were completed for all 155 patients in
the 2000 Study. 128 patients (82.5%) were still alive,
27 patients (17.4%) died, and 10 living patients
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(6.45%) did not consent to participate in the control
study. 
Both studies were financed by the State
Committee for Scientific Research from the Science
and Research Fund: KBN 4P05C05815 and KBN
2P05C03529. Both studies were accepted by the
Ethics Committee of the Pomeranian Medical
University. Data were analysed using STATISTICA
6.0 software.
Results
The results of serological tests done preo  -
peratively in 155 patients in the 2000 Study showed
specific antibodies against C. pneumoniae in IgG
class in 110 patients (71%), and in IgA class in 
90 patients (58,1%). In 81 patients (52.3%) antibodies
in both IgA class (1 : 50 or 1 : 100 solutions) and IgG
class (1 : 100 and 1 : 1000 solutions) were found. In
36 surgery patients (23.22%) no antibodies in either
of those classes were found.
Another titre assay and a comparative analysis
with the previous results was conducted on 118
patients (Table IV). In the 2000 Study IgA and IgG
class antibodies were found in 63 patients (53.39%),
but in the 2006 Study 99 patients (83.9%) had
those antibodies. The number of patients with IgA
class antibodies increased from 69 (58.47%) to 102
patients (86.4%). In 36 patients (30.5%) antibodies
were found for the first time, and in 61 patients
(51.7%) an increase of their titre occurred (p < 0.001
– χ2 test). Similarly, the number of patients with
a positive test result for IgG class antibodies
increased from 85 (72.03%) to 111 patients (94.1%).
In 26 patients (22.0%) IgG class antibodies were
found for the first time, while in 47 patients (39.8%)
an increase of their titre occurred (p < 0.001 – χ2
test). Only in 4 patients (3.38%) were no antibodies
in either IgA or IgG class found – compared to 27
patients (22.88%) from the 2000 Study. 
The growing frequency of occurrence of
increased antibody titres was confirmed by the titre
score evaluation in both 2000 and 2006 Studies
(Table V). The mean titre score for IgA and IgG
classes in the 2000 Study rose from 1.91 points to
2.99 points in the 2006 Study (p < 0.001 – χ2 test).
Respectively, we noted an increase in the antibody
titres in IgA class from 0.89 to 1.57 and in the IgG
class from 1.02 to 1.42 (p < 0.05 – χ2 test). It should
be emphasized that no acute infection symptoms
Points 0-1 (low titre) 2-3 (increased titre)4  (high titre)T otal
2000 Study 66 65 24 155
Deaths 16 7 4 27
No consent* 2 6 2 10
2006 Study 48 52 18 118
Table II. 2000 and 2006 Studies
Points 0-1 (low titer) 2-3 (increased titer)4  (high titer)T otal
2000 Study 48 52 18 118
2006 Study 15 54 49 118
Table V. Score qualification of antibody titres in patients in 2000 and 2006 Studies
Antibodies SCORE IgA SCORE IgG
SCORE 0A 1A 2A 0G 1G 2G
2000 Study 49 33 36 33 50 35
2006 Study 16 19 83 7 55 56
Table IV. Comparison of IgA and IgG class antibody levels in 118 patients
*No consent for examination in 2006
Points Antibodies Sum total of points
0-1 Low or lack of titre 0A + 0G or 1A + 0G or 0A + 1G
2-3 Increased titre  1A + 1G or 2A + 0G or 0A + 2G 
or 2A + 1G or 1A + 2G
4 High titre   2A + 2G
Table III. Clinical interpretation of antibody titres against C. pneumoniae
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were present at the time of the test in any of the
patients. Half of the surveyed patients had an
episode of respiratory tract infection within 
12 months preceding the monitoring test for
antibodies against C. pneumoniae (Table VI). Thirty
patients were treated with antibiotics for various
reasons within a year preceding the test. In 18
patients the reason for antibiotic treatment was
respiratory tract infections. The patients with the
highest titre levels of antibodies against C. pneu  -
moniae  were the ones who had been most
frequently treated with antibiotics. 
The analysis of intensification of coronary
complaints during a six-year follow-up period as
compared to the elevated levels of titres of antibodies
against C. pneumoniae is presented in Table VII. In
the 2000 Study 2 patients (1.3%) reported no
coronary complaints (CCS class I), coronary pains in
CCS class II were reported by 12 patients (12.3%),
while 67 patients (52.3%) had complaints in CCS 
class III. The rest of anginal episodes (CCS class IV)
were reported by 37 patients (34.2%). Mean
complaint degree on the CCS scale was 3.17.
In the 2006 Study, 54 patients (45.8%) did not
report any significant coronary complaints (CCS
class I). 54 patients (45.8%) reported class II
coronary complaints; 7 patients (5.9%) in class III
and only 3 patients (2.5%) were in class IV. In all the
groups, regardless of the level of antibodies against
C. pneumoniae, a statistically significant decrease
of CCS degree was noted (p < 0.05 nonparametric
test – the sign test) (Table VIII). A significant
decrease in the coronary complaints does not mean
that those patients did not require intensive
medical care. Fifty eight patients (49.2%) were
admitted to hospital for cardiological reasons during
the study period, including 10 patients (8.5%)
admitted due to recent myocardial infarction.
Another 10 patients (8.5%) were admitted to
hospital due to cerebral ischaemia symptoms. The
mean length of stay for the group of 58 patients
was 2.9 (Table IX).
Twenty seven deaths (17.4%) including 5 women
(16.1%), mean age 67.4 years (±9.4 years), and 22
deaths among men (17.7%), mean age 62.1 years
(±9.6 years), occurred in the study period. The mean
age of the deceased was 63.1 ±9.6 years. Three
patients (1.9%) died in the postoperative period and
another 4 (2.6%) during two months following the
surgery. Other patients from this group died
Points 0-1 (low titre) 2-3 (increased titre)4  (high titre)T otal Value of p
2006 Study  15 54 49 118 ns
Respiratory tract infections [%] 46.7 44.4 57.1 50.0 ns
Infection + antibiotic [%] 6.7 7.4 26.5 15.2 0.02
Antibiotic treatment [%] 13.3 22.2 32.6 25.4 ns
Table VI. Infections in respiratory tract and/or antibiotic treatment during the study
Points 0-1 (low titre) 2-3 (increased titre)4  (high titre)T otal
2000 Study Number of patients  48 52 18 118
CCS 1 1 1 0 2
CCS 2 3 6 3 12
CCS 3 26 33 8 67
CCS 4 18 12 7 37
Euroscore* 2.97 ±1.3 3.48 ±2.2 3.05 ±1.4 3.21 ±1.8
Number of bypasses 3.73 3.88 4.11 3.85
Arterial bypasses 1.77 1.48 1.83 1.65
Venous bypasses 1.96 2.40 2.28 2.20
Points 0-1 (low titre) 2-3 (increased titre)4  (high titre)T otal
2006 Study Number of patients 15 54 49 118
CCS 1 10 23 21 54
CCS 2 5 24 25 54
CCS 3 0 5 2 7
CCS 4 0 2 1 3
Table VII. Increase in coronary complaints during a six-year period following CABG
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between 9 and 76 months following the surgery
(the mean number of months following the surgery
was 51). The most frequent cause of death was
coronary condition. Obtaining reliable medical
documentation for some of the deceased was not
always possible. In two cases (7.4%) the direct cause
of death was cancer, and in another two (7.4%)
cerebral stroke.
The most deaths, i.e. 16 (24.2%), occurred in
those patients who in the 2000 Study had no
antibodies or low-titre antibodies in one class only
(0-1 points) (p < 0.05 – sign test). However, all three
post-surgery deaths (0-30 days) occurred in this
group. But they were caused by cardiac
insufficiency, and not by a chronic infection.
Respectively, in the increased titre group 7 deaths
(10.8%) occurred, and 4 deaths (16.7%) in the high
titre group (Table II). These correlations, however,
were not statistically significant in our research.
Discussion
It has been over ten years since the first papers
on the coexistence of C. pneumoniae chronic
infection symptoms and atherosclerotic disease
were published. There exist over 800 publications
on the subject, but none offers a definite answer
as to what function and impact this infection has
in the atherosclerotic disease pathogenesis.
Although, as of today, there is no incontrovertible
evidence which would clearly indicate a direct
connection between the onset of arthrosclerosis
and C. pneumoniae inflammation, many researchers
are inclined to agree with the theory that a chronic
bacterial inflammation modulates the process of
atherogenesis. Strachan et al. [10] published data
indicating a relationship between C. pneumoniae
infection and a higher mortality rate in coronary
artery disease for persons with an elevated level of
IgA class antibodies. Similarly, Lindholt et al. [11] in
their research showed elevated titres in IgA class
antibodies in abdominal aortic aneurysm patients.
Anzini  et al. [12] researched the influence of 
C. pneumoniae infection on ischaemic stroke in
young patients (aged 18-46 years) and concluded
that the elevated titre in IgA class antibodies was
significantly higher than in the control group. Zairis
et al. [13] found a relationship between chronic 
C. pneumoniae infection and progression of
Score 0-1 (low titre) 2-3 (increased titre)4  (high titre)T otal Value of p
Number of patients  15 54 49 118 ns
Myocardial infarction before 2000 10 37 28 75 ns
Another myocardial infarction after 2000 1 3 6 10 ns
Stroke after 2000 3 2 5 10 ns
Admitted to hospital after 2000 7 31 20 58 ns
Length of stay 4 2.7 2.6 2.9 ns
*Kruskal-Wallis test, **Mann-Whitney U test
2000 CCS I-III  2006
(N = 81) 0-1 (low titre) 2-3 (increased titre)4  (high titre)
–2 –1 0 1 –2 –1 0 1 –2 –1 0 1
2000 0-1 2 3 2 0 8 7 0 0 2 5 3 0 p* = 0.07
2-3 1 1 0 0 7 10 1 0 5 8 2 1 p* = NS
40 0 0 01 3 0 02 4 2 1 p** = NS
2000 CCS IV  2006
(n = 37) 0-1 (low titre) 2-3 (increased titre)4  (high titre)
–1 –2 –3 0 –1 –2 –3 0 –1 –2 –3 0
2000 0-1 2 3 0 0 3 4 1 0 2 0 0 1 p* = NS
2 - 3 0100 3202 5300 p* = NS
40 0 0 01 1 0 02 1 0 0 p** = NS
Table VIII. Improvement by 1, 2, 3 CCS classes, no change or exacerbation (0) within 6 years after CABG in the
investigated groups in both studies
Table IX. Complications occurring during a six-year study
*Kruskal-Wallis test
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atherosclerosis in patients who underwent coronary
artery stent implantation. The diagnostic criteria for
chronic C. pneumoniae infection are not clearly
defined. Some researchers focus on the titre of IgA
class antibodies; others suggest that taking into
account both IgA and IgG antibodies would provide
a more complete diagnostic picture. Yet, regardless
of which diagnostic method we favour, the proper
interpretation criteria for assaying antibody titre
must be defined. The system we used allowed for
a more objective analysis of antibodies in both
classes with their varying titres. The onset and
progression of atherosclerosis is conditioned by the
presence and expression of many risk factors. Some
of them are modifiable, e.g. the cholesterol level or
body weight; others, such as coexisting diabetes or
renal insufficiency, may be regulated by an efficient
therapy. Some other factors, such as age, increase
the risk with the passing of time. Thus when
studying the influence of the titre of antibodies
against C. pneumoniae and their late effect, we
should be aware of other factors whose impact on
the final result is not always possible to estimate.
The death of a patient during follow-up seems to
be a victory of the disease over the applied
treatment plan. The highest, statistically significant
mortality occurred in the group of patients who
either had no antibodies against C. pneumoniae or
whose titres in one of the groups was low. To some
extent, the fact could be blamed on their mean age,
which was 2.4 years higher than in the group of
surviving patients. The observations we made seem
to accord with the research results published by
Martinez et al. [14]. They reported that an increase
in titres of antibodies against C. pneumoniae
positively correlated with increasing mean age of
the study group. Particularly important is that, in
our research, we combined long-term observation
of post-CABG patients with observation of the
occurrence of positive conversion of the titres of
antibodies against C. pneumoniae. In the group with
a high antibody titre we did not find a significant
negative serum conversion, which may indicate
a reinfection and/or a chronic inflammatory process
caused by C. pneumoniae. The number of patients
who had symptoms of C. pneumoniae infection was
significantly higher between the ages of 50 and 75
than in other such studies [14-16]. The analysis of
the population of patients suffering from coronary
artery disease indicates a higher number of 
C. pneumoniae infections and a greater extent of
its development than in a population not affected
by heart ischaemia. Evaluation of the degree of
coronary complaints in postoperative patients
assessed on the CCS scale showed a significant
improvement in all the groups. In patients with
especially intensified coronary complaints before
CABG the reoccurrence of coronary complaints after
CABG depends on both degeneration processes in
the grafts and the development of alterations in
the patients’ own blood vessels. Our study does not
confirm the observations of other scientists who
describe a parallel increase in the coronary
complaints along with the increasing frequency of
high titres of antibodies against C. pneumoniae. On
the contrary, the group with the highest titre of
antibodies against C. pneumoniae from the 2006
Study reported the least reoccurrence of coronary
complaints. Our observations are contrary to those
of Gurfinkel et al. [17], which suggested that an
increase in the titres of antibodies against 
C. pneumoniae is related to the intensification of
coronary complaints and is observed more
frequently in patients suffering from acute coronary
syndrome. Frequent acute infections of patients’
upper and lower respiratory tract during the
observation period indicate a greater probability of
becoming infected by this common bacterium. It
was noted that respiratory tract infections as well
as antibiotic treatment were more frequent in the
group with the highest antibody titre than in the
remaining groups. As a result of antibiotic
treatment, the inflammatory process in the
endothelium may become temporarily suppressed,
regardless of the factors which cause that condition.
It appears that the role CP infection plays in
progression of atherosclerotic disease is not as
significant as the role other coexisting risk factors
might play, particularly in cases where an intensive
multimodal treatment is applied.
In conclusion:
1) the results of the research indicate a lack of
association between a chronic C. pneumoniae
infection and intensification of coronary
complaints evaluated on the CCS scale in
patients with CAD treated surgically during a six-
year observation period;
2) microbiological test results indicate increasing
frequency of the occurrence of high titres of
antibodies against C. pneumoniae during the
follow-up after surgical treatment of CAD;
3) surgical treatment of coronary artery disease
brought long-term relief in coronary complaints.
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